Research activity
 

 

 

Active research lines (see a selection of the latest publications):

 

 

HOME

 

 

1

Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system.

Corrado A, Aceto R, Silvestri R, Dell'Anno I, Ricci B, Miglietta S, Romei C, Giovannoni R, Poliseno L, Evangelista M, Vitiello M, Cipollini M, Garritano S, Giusti L, Zallocco L, Elisei R, Landi S, Gemignani F.Thyroid. 2020 Dec 14. doi: 10.1089/thy.2020.0366. Online ahead of print.PMID: 33308024

2

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.

Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S.Invest New Drugs. 2020 Dec 9. doi: 10.1007/s10637-020-01040-y. Online ahead of print.PMID: 33300108

3

Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.

Melaiu O, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, Grząśko N, Moreno V, Jurczyszyn A, Jerez A, Watek M, Varkonyi J, Garcia-Sanz R, Kruszewski M, Dudziński M, Kadar K, Jacobsen SEH, Mazur G, Andersen V, Rybicka M, Zawirska D, Raźny M, Zaucha JM, Ostrovsky O, Iskierka-Jazdzewska E, Reis RM, Stępień A, Beider K, Nagler A, Druzd-Sitek A, Marques H, Martěnez-Lopez J, Lesueur F, Avet-Loiseau H, Vangsted AJ, Krawczyk-Kulis M, Butrym A, Jamroziak K, Dumontet C, Vogel U, Rymko M, Pelosini M, Subocz E, Szombath G, Sarasquete ME, Silvestri R, Morani F, Landi S, Campa D, Canzian F, Gemignani F.Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33377. Online ahead of print.PMID: 33152124

4

Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide.

Silvestri R, Pucci P, De Santi C, Dell'Anno I, Miglietta S, Corrado A, Nicolí V, Marolda D, Cipollini M, Pellegrino E, Evangelista M, Bonotti A, Foddis R, Cristaudo A, Landi S, Gemignani F.Front Genet. 2020 Aug 18;11:975. doi: 10.3389/fgene.2020.00975. eCollection 2020.PMID: 33014022 Free PMC article.

Item in Clipboard

5

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report).

Dell'Anno I, Barone E, Mutti L, Rassl DM, Marciniak SJ, Silvestri R, Landi S, Gemignani F.J Transl Med. 2020 Sep 4;18(1):341. doi: 10.1186/s12967-020-02487-6.PMID: 32887638 Free PMC article.

Item in Clipboard

6

EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma.

Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, Melaiu O, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, Landi S.Int J Mol Sci. 2020 Jul 9;21(14):4856. doi: 10.3390/ijms21144856.PMID: 32659970 Free PMC article.

Item in Clipboard

7

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.

Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F.Semin Cancer Biol. 2020 Jul 10:S1044-579X(20)30156-5. doi: 10.1016/j.semcancer.2020.07.001. Online ahead of print.PMID: 32659257 Review.

8

DNA polymerases in the risk and prognosis of colorectal and pancreatic cancers.

Silvestri R, Landi S.Mutagenesis. 2019 Dec 19;34(5-6):363-374. doi: 10.1093/mutage/gez031.PMID: 31647559 Review.

Item in Clipboard

9

Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis.

Cipollini M, Luisi S, Piomboni P, Luddi A, Landi D, Melaiu O, Figlioli G, Garritano S, Cappelli V, Viganň P, Gemignani F, Petraglia F, Landi S.Fertil Steril. 2019 Aug;112(2):343-352.e1. doi: 10.1016/j.fertnstert.2019.04.011. Epub 2019 Jun 27.PMID: 31256999

Item in Clipboard

10

DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility.

Pardini B, Corrado A, Paolicchi E, Cugliari G, Berndt SI, Bezieau S, Bien SA, Brenner H, Caan BJ, Campbell PT, Casey G, Chan AT, Chang-Claude J, Cotterchio M, Gala M, Gallinger SJ, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hsu L, Huyghe J, Jenkins MA, Le Marchand L, Lin Y, Lindor NM, Nan H, Newcomb PA, Ogino S, Potter JD, Schoen RE, Slattery ML, White E, Vodickova L, Vymetalkova V, Vodicka P, Gemignani F, Peters U, Naccarati A, Landi S.Int J Cancer. 2020 Jan 15;146(2):363-372. doi: 10.1002/ijc.32516. Epub 2019 Jul 4.PMID: 31209889 Free PMC article.

Item in Clipboard

11

The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans.

Pellč L, Carlsson H, Cipollini M, Bonotti A, Foddis R, Cristaudo A, Romei C, Elisei R, Gemignani F, Törnqvist M, Landi S.Arch Toxicol. 2018 Jun;92(6):2137-2140. doi: 10.1007/s00204-018-2211-2. Epub 2018 May 10.PMID: 29748789

Item in Clipboard

12

Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Barone E, Gemignani F, Landi S.J Thorac Dis. 2018 Jan;10(Suppl 2):S369-S382. doi: 10.21037/jtd.2017.10.158.PMID: 29507807 Free PMC article. Review.

Item in Clipboard

13

The genetic susceptibility in the development of malignant pleural mesothelioma.

Melaiu O, Gemignani F, Landi S.J Thorac Dis. 2018 Jan;10(Suppl 2):S246-S252. doi: 10.21037/jtd.2017.10.41.PMID: 29507792 Free PMC article. Review.

Item in Clipboard

14

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.PMID: 28600498 Free PMC article.

15

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellč L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.PMID: 28435517 Free PMC article.

16

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellč L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25.PMID: 28343162

17

Bonafide Targets of Deregulated microRNAs in Non-Small Cell Lung Cancer as Tool to Identify Novel Therapeutic Targets: A Review.

Cipollini M, Landi S, Gemignani F.Curr Pharm Des. 2017;23(1):55-72. doi: 10.2174/1381612822666161006152838.PMID: 27719642 Review.

18

Environmental risk factors for pancreatic cancer: an update.

Barone E, Corrado A, Gemignani F, Landi S.Arch Toxicol. 2016 Nov;90(11):2617-2642. doi: 10.1007/s00204-016-1821-9. Epub 2016 Aug 18.PMID: 27538405 Review.

19

Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma.

Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, Melaiu O, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddis R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, Landi S.DNA Repair (Amst). 2016 May;41:27-31. doi: 10.1016/j.dnarep.2016.03.011. Epub 2016 Mar 31.PMID: 27062014

20

Targeting hypoxic response for cancer therapy.

Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S.Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229.PMID: 26859576 Free PMC article. Review.

21

A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma.

Figlioli G, Elisei R, Romei C, Melaiu O, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S.Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):700-13. doi: 10.1158/1055-9965.EPI-15-0652. Epub 2016 Feb 3.PMID: 26843521 Free article.

22

Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.

Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S.Arch Toxicol. 2016 Dec;90(12):3099-3109. doi: 10.1007/s00204-016-1660-8. Epub 2016 Jan 19.PMID: 26783003

23

Expression status of candidate genes in mesothelioma tissues and cell lines.

Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13.PMID: 25771974 Clinical Trial.

24

A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.PMID: 25436799 Free article.

25

MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Cipollini M, Landi S, Gemignani F.Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014.PMID: 25114582 Free PMC article. Review.

26

Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.

Figlioli G, Köhler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Velázquez A, Jarząb B, Landi S, Hemminki K, Försti A, Gemignani F.J Clin Endocrinol Metab. 2014 Oct;99(10):E2084-92. doi: 10.1210/jc.2014-1734. Epub 2014 Jul 16.PMID: 25029422

27

MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014.PMID: 24465798 Free PMC article.

28

Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24.

Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L, Frixa T, Landi D, Cancemi L, De Santi C, Melaiu O, Foddis R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, Landi S.Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2121-5. doi: 10.1158/1055-9965.EPI-13-0790. Epub 2013 Sep 5.PMID: 24008490 Free article.

29

More targets, more pathways and more clues for mutant p53.

Garritano S, Inga A, Gemignani F, Landi S.Oncogenesis. 2013 Jul 1;2(7):e54. doi: 10.1038/oncsis.2013.15.PMID: 23817466 Free PMC article.

30

Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.

Figlioli G, Landi S, Romei C, Elisei R, Gemignani F.Mutat Res. 2013 Jan-Mar;752(1):36-44. doi: 10.1016/j.mrrev.2012.09.002. Epub 2012 Oct 8.PMID: 23059849 Review.

31

The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome.

Landi S, Putignano E, Boggio EM, Giustetto M, Pizzorusso T, Ratto GM.Sci Rep. 2011;1:45. doi: 10.1038/srep00045. Epub 2011 Jul 25.PMID: 22355564 Free PMC article.

32

Role of variations within microRNA-binding sites in cancer.

Landi D, Gemignani F, Landi S.Mutagenesis. 2012 Mar;27(2):205-10. doi: 10.1093/mutage/ger055.PMID: 22294768

33

Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome.

Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, Novotny J, Barale R, Landi S.Cancer. 2012 Oct 1;118(19):4670-80. doi: 10.1002/cncr.27435. Epub 2012 Jan 26.PMID: 22282400 Free article.

34

A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.

Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F, Pellegrini S, Landi S.Mutat Res. 2012 Apr-Jun;750(2):132-140. doi: 10.1016/j.mrrev.2011.12.003. Epub 2011 Dec 15.PMID: 22198210 Review.

35

Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Gemignani F, Landi S.Int J Biol Markers. 2011 Apr-Jun;26(2):117-23. doi: 10.5301/JBM.2011.8332.PMID: 21574151 Free article.

36

Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma.

Cancemi L, Romei C, Bertocchi S, Tarrini G, Spitaleri I, Cipollini M, Landi D, Garritano S, Pellegrini G, Cristaudo A, Pinchera A, Barale R, Elisei R, Landi S, Gemignani F.Int J Cancer. 2011 Dec 15;129(12):2816-24. doi: 10.1002/ijc.25937. Epub 2011 Apr 25.PMID: 21520031 Free article.

37

Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer.

Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, Canzian F, Barale R, Gemignani F, Landi S.Mutat Res. 2011 Dec 1;717(1-2):109-15. doi: 10.1016/j.mrfmmm.2010.10.002. Epub 2010 Oct 30.PMID: 20971123 Review.

38

Prediction of the biological effect of polymorphisms within microRNA binding sites.

Landi D, Barale R, Gemignani F, Landi S.Methods Mol Biol. 2011;676:197-210. doi: 10.1007/978-1-60761-863-8_14.PMID: 20931399

39

DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region.

Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, Landi S.Hum Mutat. 2010 Apr;31(4):456-65. doi: 10.1002/humu.21214.PMID: 20127977

40

Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Landi D, Gemignani F, Landi S.Occup Environ Med. 2010 Apr;67(4):233-6. doi: 10.1136/oem.2009.049205. Epub 2009 Oct 26.PMID: 19858537

41

Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism.

Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, Ceppi M, Spitaleri I, Cipollini M, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Ugolini D, Mutti L, Bonassi S, Landi S.Mutat Res. 2009 Dec 1;671(1-2):76-83. doi: 10.1016/j.mrfmmm.2009.09.003. Epub 2009 Sep 12.PMID: 19751749

42

Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature.

Landi S.Mutat Res. 2009 Mar-Jun;681(2-3):299-307. doi: 10.1016/j.mrrev.2008.12.001. Epub 2008 Dec 27.PMID: 19150414 Review.

43

Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer.

Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Försti A, Hemminki K, Canzian F, Landi S.Carcinogenesis. 2008 Mar;29(3):579-84. doi: 10.1093/carcin/bgm304. Epub 2008 Jan 12.PMID: 18192692

44

A catalog of polymorphisms falling in microRNA-binding regions of cancer genes.

Landi D, Gemignani F, Barale R, Landi S.DNA Cell Biol. 2008 Jan;27(1):35-43. doi: 10.1089/dna.2007.0650.PMID: 17941804

45

Single tube genotyping of GSTM1, GSTT1 and TP53 polymorphisms by multiplex PCR.

Bottari F, Landi S, Gemignani F.DNA Seq. 2006 Oct;17(5):396-9. doi: 10.1080/10425170600752569.PMID: 17343214

46

Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma.

Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Mutti L, Puntoni R.Int J Cancer. 2007 Jun 15;120(12):2739-43. doi: 10.1002/ijc.22590.PMID: 17290392 Free article.

47

Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk.

Landi S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, de Oca J, Capella G, Canzian F, Moreno V; Bellvitge Colorectal Cancer Study Group.Eur J Cancer. 2007 Mar;43(4):762-8. doi: 10.1016/j.ejca.2006.10.024. Epub 2007 Jan 26.PMID: 17258448

48

DNA repair and cell cycle control genes and the risk of young-onset lung cancer.

Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gioia-Patricola L, Hall J, Boffetta P, Hung RJ, Brennan P.Cancer Res. 2006 Nov 15;66(22):11062-9. doi: 10.1158/0008-5472.CAN-06-1039.PMID: 17108146 Free article.

49

Polymorphisms within inflammatory genes and colorectal cancer.

Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, Moreno V.J Negat Results Biomed. 2006 Oct 24;5:15. doi: 10.1186/1477-5751-5-15.PMID: 17062130 Free PMC article.